Olmesartan/amlodipine: Blood pressure lowering and beyond in special populations

Therapeutic Advances in Cardiovascular Disease

Volumn 6, Issue 1, 2012, Pages 31-44

  Erdine, Serap ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

amlodipine besylate; hypertension; metabolic syndrome; olmesartan medoxomil; single pill combination

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS OLMESARTAN; ANGIOTENSIN 1 RECEPTOR; ATENOLOL; BENAZEPRIL; BENDROFLUMETHIAZIDE; HYDROCHLOROTHIAZIDE; LOSARTAN; OLMESARTAN; PERINDOPRIL; RAMIPRIL; TELMISARTAN; VALSARTAN;

ARTERIAL WALL THICKNESS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; EUROPE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INCIDENCE; INFLAMMATION; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PILL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DRUG COMBINATIONS; HUMANS; HYPERTENSION; IMIDAZOLES; PRACTICE GUIDELINES AS TOPIC; TETRAZOLES;

EID: 84856699409     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944711432902     Document Type: Article

References (63)

1. Adeghate E. Schattner P. Dunn E. (2006) An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci 1084: 1–29.
2. Bahlmann F.H. de Groot K. Mueller O. Hertel B. Haller H. Fliser D. (2005) Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 45: 526–529.
3. Beckett N.S. Peters R. Fletcher A.E. Staessen J.A. Liu L. Dumitrascu D. et al. (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358: 1887–1898.
4. Belletti D.A. Zacker C. Wogen J. (2010) Effect of cardiometabolic risk factors on hypertension management: a cross-sectional study among 28 physician practices in the United States. Cardiovasc Diabetol 9: 7.
5. Bestehorn K. Wahle K. Kirch W. (2008) Stroke risk screening of adults with hypertension: prospective cross-sectional study in primary care. Clin Drug Investig 28: 281–289.
6. Bramlage P. Pittrow D. Wittchen H.U. Kirch W. Boehler S. Lehnert H. et al. (2004) Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 17: 904–910.
7. Bramlage P. Wolf W.P. Stuhr T. Fronk E.M. Erdlenbruch W. Ketelhut R. et al. (2010 a) Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice. Vasc Health Risk Manag 6: 803–811.
8. Bramlage P. Wolf W.P. Fronk E.M. Stuhr T. Erdlenbruch W. Wasem J. et al. (2010 b) Improving quality of life in hypertension management using a fixed-dose combination of olmesartan and amlodipine in primary care. Expert Opin Pharmacother 11: 2779–2790.
9. Chrysant S.G. Lee J. Melino M. Karki S. Heyrman R. (2010 a) Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. J Hum Hypertens 24:730–738.
10. Chrysant S.G. Melino M. Fernandez V. Lee J. Heyrman R. (2010 b) Efficacy and safety of combination olmesartan medoxomil (Om)+amlodipine besylate (Aml)+hydrochlorothiazide (HCTZ) in patients with hypertension: analysis by age and gender. J Clin Hypertens (Greenwich) 12: A30–A31.
11. Chrysant S.G. Melino M. Karki S. Lee J. Heyrman R. (2008) The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: coach, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 30: 587–604.
12. Chrysant S.G. Oparil S. Melino M. Karki S. Lee J. Heyrman R. (2009) Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens (Greenwich) 11: 475–482.
13. Dahlof B. Devereux R.B. Kjeldsen S.E. Julius S. Beevers G. de Faire U. et al. (2002) Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995–1003.
14. Dahlof B. Sever P.S. Poulter N.R. Wedel H. Beevers D.G. Caulfield M. et al. (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366: 895–906.
15. de La Sierra A. (2009) Efficacy of olmesartan medoxomil / amlodipine (Olm/Aml) plus amlodipine (Aml) in age defined subgroups of moderate-to-severe hypertensive patients. J Hypertens 27(Suppl. 4): S131.
16. Fabia M.J. Abdilla N. Oltra R. Fernandez C. Redon J. (2007) Antihypertensive activity of angiotensin II AT 1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 25: 1327–1336.
17. Fliser D. Buchholz K. Haller H. (2004) Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110: 1103–1107.
18. Gradman A.H. Basile J.N. Carter B.L. Bakris G.L. Materson B.J. Black H.R. et al. (2010) Combination therapy in hypertension. J Am Soc Hypertens 4: 90–98.
19. Grundy S.M. (2008) Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 28: 629–636.
20. Grundy S.M. Cleeman J.I. Daniels S.R. Donato K.A. Eckel R.H. Franklin B.A. et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association / National Heart, Lung, and Blood Institute scientific statement. Circulation 112: 2735–2752.
21. Haria M. Wagstaff A.J. (1995) Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 50: 560–586.
22. Ichihara A. Kaneshiro Y. Sakoda M. Takemitsu T. Itoh H. (2007) Add-on amlodipine improves arterial function and structure in hypertensive patients treated with an angiotensin receptor blocker. J Cardiovasc Pharmacol 49: 161–166.
23. International Association for the Study of Obesity (2011) IASO Prevalence Data: Global Prevalence of Adult Obesity, International Association for the Study of Obesity. http://www.iaso.org/site_media/uploads/Prevalence_of_Adult_Obesity_September_2011.pdf (accessed 19 October 2011).
24. Ishimitsu T. Minami J. Kawano Y. Numabe A. Takishita S. Matsuoka H. (1999) Amlodipine, a long-acting calcium channel blocker, attenuates morning blood pressure rise in hypertensive patients. Clin Exp Pharmacol Physiol 26: 500–504.
25. Jamerson K. Weber M.A. Bakris G.L. Dahlof B. Pitt B. Shi V. et al. (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359: 2417–2428.
26. Julius S. Kjeldsen S.E. Weber M. Brunner H.R. Ekman S. Hansson L. et al. (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the Value Randomised Trial. Lancet 363: 2022–2031.
27. Kannel W.B. (1996) Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 275: 1571–1576.
28. Kannel W.B. Gordan T. (1978) Evaluation of cardiovascular risk in the elderly: the Framingham Study. Bull N Y Acad Med 54: 573–591.
29. Kearney P.M. Whelton M. Reynolds K. Muntner P. Whelton P.K. He J. (2005) Global burden of hypertension: analysis of worldwide data. Lancet 365: 217–223.
30. Kereiakes D. Chrysant S.G. Melino M. Fernandez V. Lee J. Heyrman R. (2010) Efficacy and safety of combination olmesartan medoxomil (Om)+amlodipine besylate (Aml)+hydrochlorothiazide (HCTZ) based on severity of hypertension: the Trinity Study. J Clin Hypertens (Greenwich) 12: A37.
31. Laeis A. Ammentorp B. (2009) Efficacy and tolerability of olmesartan medoxomil / amlodipine (Olm/Aml) by baseline hypertension severity subgroup in patients with moderate to severe hypertension. J Hypertens 27(Suppl. 4): S432.
32. Law M.R. Wald N.J. Morris J.K. Jordan R.E. (2003) Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326: 1427.
33. Mancia G. de Backer G. Dominiczak A. Cifkova R. Fagard R. Germano G. et al. (2007) 2007 guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25: 1105–1187.
34. Mancia G. Laurent S. Agabiti-Rosei E. Ambrosioni E. Burnier M. Caulfield M.J. et al. (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 27: 2121–2158.
35. Martinez-Martin F.J. Rodriguez-Rosas H. Lopez-Fernandez J. (2011) Olmesartan plus amlodipine (but not plus hydrochlorothiazide) may improve oxidative stress and endothelial dysfunction in hypertensive patients with metabolic syndrome. J Hypertens 29 (e-Suppl. A): e388 (PP.326.323).
36. Martinez-Martin F.J. Rodriguez-Rosas H. Peiro-Martinez I. Soriano-Perera P. Pedrianes-Martin P. Comi-Diaz C. (2010) Olmesartan / amlodipine vs olmesartan / hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS Study. J Hum Hypertens 25: 346–353.
37. Messerli F.H. (2002) Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Rep 4: 479–482.
38. Neutel J.M. (1999) Low-dose antihypertensive combination therapy: its rationale and role in cardiovascular risk management. Am J Hypertens 12: 73S–79S.
39. Oparil S. Chrysant S.G. Melino M. Lee J. Karki S. Heyrman R. (2010 a) Long-term efficacy of a combination of amlodipine and olmesartan medoxomil+/−hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the Coach Trial. J Hum Hypertens 24:831–838
40. Oparil S. Lee J. Karki S. Melino M. (2009) Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. J Cardiovasc Pharmacol 54: 427–436.
41. Oparil S. Melino M. Lee J. Fernandez V. Heyrman R. (2010 b) Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the Trinity Multicenter, Randomized, Double-Blind, 12-Week, Parallel-Group Study. Clin Ther 32: 1252–1269.
42. Patel A. Macmahon S. Chalmers J. Neal B. Woodward M. Billot L. et al. (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the Advance Trial): a randomised controlled trial. Lancet 370: 829–840.
43. Progress Collaborative Group (2001) Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033–1041.
44. Ram C.V. Sachson R. Littlejohn T. Qian C. Shojaee A. Stoakes K.A. et al. (2011) Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. Am J Cardiol 107: 1346–1352.
45. Schmieder R.E. Bohm M. (2011) Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. J Hum Hypertens 25: 354–363.
46. Shaw J.E. Sicree R.A. Zimmet P.Z. (2009) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87: 4–14.
47. Smith R.D. Yokoyama H. Averill D.B. Schiffrin E.L. Ferrario C.M. (2008) Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II Receptors. J Am Soc Hypertens 2: 165–172.
48. Stumpe K. Agabiti-Rosei E. Zielinski T. Schremmer D. Scholze J. Laeis P. et al. (2007) Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan Atherosclerosis Regression Evaluation (MORE) Study. Ther Adv Cardiovasc Dis 1: 97–106.
49. Suh D.C. Kim C.M. Choi I.S. Plauschinat C.A. Barone J.A. (2009) Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States: 1988–2004. J Hypertens 27: 1908–1916.
50. Swinburn B.A. Sacks G. Hall K.D. Mcpherson K. Finegood D.T. Moodie M.L. et al. (2011) The global obesity pandemic: shaped by global drivers and local environments. Lancet 378: 804–814.
51. Terpstra W.F. May J.F. Smit A.J. Graeff P.A. Meyboom-de Jong B. Crijns H.J. (2004) Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the Elvera Trial). J Hypertens 22: 1309–1316.
52. Toba H. Nakagawa Y. Miki S. Shimizu T. Yoshimura A. Inoue R. et al. (2005) Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methyl ester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine. Hypertens Res 28: 689–700.
53. Turgan N. Habif S. Kabaroglu C.G. Mutaf I. Ozmen D. Bayindir O. et al. (2003) Effects of the calcium channel blocker amlodipine on serum and aortic cholesterol, lipid peroxidation, antioxidant status and aortic histology in cholesterol-fed rabbits. J Biomed Sci 10: 65–72.
54. Volpe M. Brommer P. Haag U. Miele C. (2009 a) Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig 29: 11–25.
55. Volpe M. Miele C. Haag U. (2009 b) Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin Drug Investig 29: 381–391.
56. Wald D.S. Law M. Morris J.K. Bestwick J.P. Wald N.J. (2009) Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 122: 290–300.
57. Weir M.R. Hsueh W.A. Nesbitt S.D. Littlejohn T.J. III Graff A. Shojaee A. et al. (2011) A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil +/− hydrochlorothiazide. J Clin Hypertension 13: 404–412.
58. Williams B. Lacy P.S. Thom S.M. Cruickshank K. Stanton A. Collier D. et al. (2006) Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation 113: 1213–1225.
59. Yang W. Chang J. Kahler K.H. Fellers T. Orloff J. Wu E.Q. et al. (2010) Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin 26: 2065–2076.
60. Yusuf S. Teo K.K. Pogue J. Dyal L. Copland I. Schumacher H. et al. (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547–1559.
61. Zannad F. (2000) The potential advantages of a modern antihypertensive therapy in the elderly. J Cardiovasc Pharmacol 35: S19–S23
62. Zeglin M.A. Pacos J. Bisognano J.D. (2009) Hypertension in the very elderly: brief review of management. Cardiol J 16: 379–385.
63. Ziesche R. Petkov V. Lambers C. Erne P. Block L.H. (2004) The calcium channel blocker amlodipine exerts its anti-proliferative action via P21(WAF1/CIP1) gene activation. FASEB J 18: 1516–1523.